Cargando…

1587. SOLAR 12-Month North American Results: Randomized Switch Trial of CAB+RPV LA vs. Oral BIC/FTC/TAF

BACKGROUND: Cabotegravir + rilpivirine (CAB+RPV) administered monthly or every 2 months (Q2M) is the only complete long-acting (LA) regimen for maintaining HIV-1 suppression and may address challenges associated with daily oral therapy. In the Phase 3b SOLAR study, switching to CAB+RPV LA Q2M was no...

Descripción completa

Detalles Bibliográficos
Autores principales:	McKellar, Mehri, Teichner, Paula, Bettacchi, Christopher, Angel, Jonathan, Gordon, Lori A, Sutton, Kenneth, Sutherland-Phillips, Denise, Talarico, Christine L, Urbaityte, Rimgaile, Solingen-Ristea, Rodica Van, Baugh, Bryan, D’Amico, Ronald, van Wyk, Jean A
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2023
Materias:	Abstract
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10676875/ http://dx.doi.org/10.1093/ofid/ofad500.1422

Ejemplares similares

Short-term Adverse Events With BIC/FTC/TAF: Postmarketing Study
por: Hayes, Edwin, et al.
Publicado: (2020)

638. Safety, Efficacy, and Durability of Long-Acting CAB and RPV as Maintenance Therapy for HIV-1 Infection: LATTE-2 Week 256 Results
por: Smith, Graham, et al.
Publicado: (2020)

2508. Virologic Suppression in Patients Switched to BIC/TAF/FTC with Baseline NRTI and/or INSTI Resistance
por: Natali, Kayla M, et al.
Publicado: (2019)

Impact of switching to TAF/FTC/RPV, TAF/FTC/EVG/cobi and ABC/3TC/DTG on cardiovascular risk and lipid profile in people living with HIV: a retrospective cohort study
por: Giacomelli, Andrea, et al.
Publicado: (2021)

1598. Predictive equations for immune recovery at 48 weeks of BIC/FTC/TAF treatment in Virologically Suppressed PLWHIV.
por: Tomé, Roberto Pedrero, et al.
Publicado: (2023)

1571. BIC/FTC/TAF in Virologically Suppressed PLWHIV: 48-96 weeks RETROBIC Multicenter Cohort study results.
por: Estévez, Samuel, et al.
Publicado: (2023)

Switching to coformulated rilpivirine (RPV), emtricitabine (FTC) and tenofovir alafenamide from either RPV, FTC and tenofovir disoproxil fumarate (TDF) or efavirenz, FTC and TDF: 96‐week results from two randomized clinical trials
por: Hagins, D, et al.
Publicado: (2018)

1448. Forgiveness of BIC/FTC/TAF: In Vitro Simulations of Intermittent Poor Adherence Find Limited HIV-1 Breakthrough and High Barrier to Resistance
por: Mulato, Andrew, et al.
Publicado: (2020)

1003. BIC/FTC/TAF Maintains Viral Suppression in Patients with Documented M184V/I Mutations: A Real World Experience
por: Chamberlain, Nicholas, et al.
Publicado: (2020)

Viro-Immunological, Clinical Outcomes and Costs of Switching to BIC/TAF/FTC in a Cohort of People Living with HIV: A 48-Week Prospective Analysis
por: Mazzitelli, Maria, et al.
Publicado: (2022)

Outcomes After Switching to BIC/FTC/TAF in Patients with Virological Failure to Protease Inhibitors or Non-Nucleoside Reverse Transcriptase Inhibitors: A Real-World Cohort Study
por: Chang, Hui-Min, et al.
Publicado: (2021)

1024. Impact of Treatment Adherence on Efficacy of DTG/3TC and DTG + TDF/FTC: Pooled Analysis of the GEMINI 1 and 2 Clinical Trials
por: Ait-Khaled, Mounir, et al.
Publicado: (2020)

Switching at Low HIV-1 RNA into Fixed Dose Combinations: TDF/FTC/RPV is non-inferior to TDF/FTC/EFV in first-line suppressed patients living with HIV
por: Munderi, Paula, et al.
Publicado: (2019)

Lipidomics Reveals Reduced Inflammatory Lipid Species and Storage Lipids after Switching from EFV/FTC/TDF to RPV/FTC/TDF: A Randomized Open-Label Trial
por: Curran, Adrian, et al.
Publicado: (2020)

1567. Perspectives of People with HIV (PWH) 6 Months Following a Switch to Cabotegravir and Rilpivirine Long-acting (CAB+RPV LA) in an Observational Real-world US Study (BEYOND)
por: Dandachi, Dima, et al.
Publicado: (2023)

1024. Real-world Adherence and Persistence with Long-Acting Cabotegravir Plus Rilpivirine (CAB+RPV LA) Compared to Oral Antiretroviral Therapy (ART) Among People with HIV (PWH) in the US: The ABOVE Study
por: Garris, Cindy, et al.
Publicado: (2023)

877. North American Phase 3/3b Experience with Long-Acting Cabotegravir and Rilpivirine: Efficacy, Safety, and Virologic Outcomes
por: Taiwo, Babafemi O, et al.
Publicado: (2021)

Switch to Stribild versus continuation of NVP or RPV with FTC and TDF in virologically suppressed HIV adults: a STRATEGY-NNRTI subgroup analysis
por: Stellbrink, Hans-Juergen, et al.
Publicado: (2014)

Hepatic safety of RPV/FTC/TDF single tablet regimen in HIV/HCV-coinfected patients. Preliminary results of the hEPAtic Study
por: Neukam, Karin, et al.
Publicado: (2014)

ACTG-HIV symptoms changes in patients switched to RPV/FTC/TDF due to previous intolerance to CART. Interim analysis of the PRO-STR study
por: Podzamczer, Daniel, et al.
Publicado: (2014)

2840. Long-term Efficacy, Safety, and Durability of CAB and RPV as Two Drug Oral Maintenance Therapy: LATTE Week 312 Results
por: Margolis, David, et al.
Publicado: (2019)

1002. A Daily Single Tablet Regimen (STR) of Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF) in Virologically-Suppressed Adults Living with HIV and End Stage Renal Disease on Chronic Hemodialysis
por: Eron, Joseph J, et al.
Publicado: (2020)

Lipid changes in HIV-patients switching to the coformulated single tablet FTC/RPV/TDF (Eviplera(®)). Efficacy and safety analysis. GeSida Study 8114
por: Pérez-Hernández, Isabel A, et al.
Publicado: (2014)

1607. Clinical Outcomes at Month 6 after Initiation of Cabotegravir and Rilpivirine Long-Acting (CAB + RPV LA) in an Observational Real-World Study (BEYOND)
por: Sinclair, Gary I, et al.
Publicado: (2023)

Severe rhabdomyolysis-induced acute kidney injury following concomitant use of Genvoya® (EVG/COBI/FTC/TAF) and simvastatin; a case report
por: Godinho, Rita, et al.
Publicado: (2019)

P1587: IS IT SAFE FOR OUR PATIENTS TO COME OUT?
por: Jabbar Al-Obaidi, M., et al.
Publicado: (2022)

Rpv29, Rpv30 and Rpv31: Three Novel Genomic Loci Associated With Resistance to Plasmopara viticola in Vitis vinifera
por: Sargolzaei, Maryam, et al.
Publicado: (2020)

SUSY RPV Searches
por: Zhuang, Xuai
Publicado: (2017)

RPV Models Overview
por: Nangia, Saurabh
Publicado: (2022)

2495. Pharmacokinetics of Cabotegravir (CAB) and Rilpivirine (RPV) Long-Acting (LA) Injectables in HIV-infected Individuals through 48 Weeks in the FLAIR and ATLAS Phase 3 Studies
por: Patel, Parul, et al.
Publicado: (2019)

Airs mis en musique a quatre parties (1587)
por: Planson, Jehan

Grapevine Rpv3-, Rpv10- and Rpv12-mediated defense responses against Plasmopara viticola and the impact of their deployment on fungicide use in viticulture
por: Wingerter, Chantal, et al.
Publicado: (2021)

538 A Retrospective Study to Evaluate the Safety of Switching Antiretroviral Therapy (ART) to Rilpivirine/Tenofovir Disoproxil Fumarate/Emtricitabine (RPV/TDF/FTC) STR in Virologically Suppressed HIV-Infected Patients
por: Monczor, Ana, et al.
Publicado: (2014)

Exploration of the Hsa-miR-1587–Protein Interaction and the Inhibition to CASK
por: Zhang, Lulu, et al.
Publicado: (2021)

LB-8. Summary of COVID-Related Impact on Cabotegravir and Rilpivirine Long-Acting (CAB+RPV LA) Dosing Across the Six Ongoing Global Phase IIb and IIIb Clinical Trials
por: D'Amico, Ronald, et al.
Publicado: (2020)

RPV SUSY searches at ATLAS and CMS
por: Pettersson, Nora Emilia
Publicado: (2015)

Current status of RPV searches at ATLAS
por: Blocker, C
Publicado: (2013)

Two-omics data revealed commonalities and differences between Rpv12- and Rpv3-mediated resistance in grapevine
por: Chitarrini, Giulia, et al.
Publicado: (2020)

The CAB software package
por: Perrin, Yves, et al.
Publicado: (1984)

A Cab Ride
por: Judson, Seth D.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_80ad8gfcb418qea0h1p7tdmclo